

Commission Implementing Decision (EU) 2019/1244 of 1 July 2019 amending Decision 2002/364/EC as regards requirements for HIV and HCV antigen and antibody combined tests and as regards requirements for nucleic acid amplification techniques with respect to reference materials and qualitative HIV assays (notified under document C(2019) 4632) (Text with EEA relevance)

- Article 1 The Annex to Decision 2002/364/EC is amended in accordance with...
- Article 2 This Decision shall apply from 2 July 2020. Until that date,...
- Article 3 This Decision is addressed to the Member States.
Signature

ANNEX

The Annex to Decision 2002/364/EC is amended as follows:
Sub-section 3.1.1 is replaced by the following: 3.1.1 Devices which...

Changes to legislation: There are currently no known outstanding effects for the
Commission Implementing Decision (EU) 2019/1244. (See end of Document for details)

- (1) [OJ L 331, 7.12.1998, p. 1.](#)
- (2) Commission Decision 2002/364/EC of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices ([OJ L 131, 16.5.2002, p. 17.](#))
- (3) Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices ([OJ L 189, 20.7.1990, p. 17.](#))

Changes to legislation:

There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2019/1244.